References
- Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between
clinical patterns and causes of erythema multiforme majus,
Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of
an international prospective study. Arch Dermatol 2002;
138:1019–24.
- J.-C. Roujeau, J. P. Kelly, L. Naldi et al., “Medication use and the
risk of Stevens–Johnson syndrome or toxic epidermal necrolysis,”New England Journal of Medicine , vol. 333, no. 24, pp.
1600–1608, 1995.
- Y. Finkelstein, G. S. Soon, P. Acuna et al., “Recurrence and outcomes
of Stevens-Johnson syndrome and toxic epidermal necrolysis in
children,” Pediatrics , vol. 128, no. 4, pp. 723–728, 2011.
- E. P. Borrelli, E. Y. Lee, A. M. Descoteaux, S. J. Kogut, and A. R.
Caffrey, “Stevens-Johnson syndrome and toxic epidermal necrolysis
with antiepileptic drugs: an analysis of the US food and drug
administration adverse event reporting system,” Epilepsia, vol. 59,
no. 12, pp. 2318–2324, 2018
- Micheletti RG, Chiesa-Fuxench Z, Noe MH, Stephen S, Aleshin M, Agarwal
A, et al. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A
Multicenter Retrospective Study of 377 Adult Patients from the United
States. J Invest Dermatol (2018) 138(11):2315–21. doi:
10.1016/j.jid.2018.04.027
- J. T. Masuka, S. Khoza, and D. Chibanda, “An interesting case of
carbamazepine-induced stevens-johnson syndrome,” Drug Safety—Case
Reports, vol. 6, no. 1, p. 1, 2018.
- Abuzneid YS, Alzeerelhouseini HI, Rabi D, Hilail I, Rjoob H, Rabee A,
Amro N, Qafisheh Q, Kharraz M. Carbamazepine Induced Stevens-Johnson
Syndrome That Developed into Toxic Epidermal Necrolysis: Review of the
Literature. Case Reports in Dermatological Medicine. 2022 May 6;2022.
- Imatoh T, Saito Y. Associations between Stevens–Johnson syndrome and
infection: overview of pharmacoepidemiological studies. Frontiers in
Medicine. 2021 Mar 26;8:644871.
- Stevens-Johnson Syndrome: Practice Essentials, Background,
Pathophysiology. eMedicine [Internet]. 2019 Nov 10; Available
from: https://emedicine.medscape.com/article/1197450-overview ̵